CEBPA and leukemia: Among them, as the only FTO inhibitor that has been tested through systemic administration in mice, R-2HG inhibited FTO activity and increased global m6A modification, which in turn decreased c-Myc and CEBPA m6A modification, leading to leukemia cell growth inhibition, cell-cycle arrest, and apoptosis20.